Immune checkpoint inhibitors have radically changed the treatment approach to metastatic renal cell carcinoma (mRCC). In the present article, we reported and discussed the available data with immunocombinations in mRCC, offering new perspectives in the treatment landscape of these patients. We discussed the main results of pivotal clinical trials of immune checkpoint inhibitors in the treatment of mRCC. Moreover, we discussed novel immuno-based treatments currently under investigation in ongoing clinical trials. Renal cell carcinoma is a particularly immunogenic tumor and immunotherapy is a pivotal treatment approach. A wide series of clinical trials is exploring novel promising immunocombinations in patients with renal cell carcinoma.
Designing novel immunocombinations in metastatic renal cell carcinoma / Santoni, M.; Massari, F.; Aurilio, G.; Mollica, V.; Cimadamore, A.; Lopez-Beltran, A.; Cheng, L.; Battelli, N.; Nole, F.; Montironi, R.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 12:17(2020), pp. 1257-1268. [10.2217/imt-2020-0144]
Designing novel immunocombinations in metastatic renal cell carcinoma
Santoni M.;Cimadamore A.;Montironi R.
2020-01-01
Abstract
Immune checkpoint inhibitors have radically changed the treatment approach to metastatic renal cell carcinoma (mRCC). In the present article, we reported and discussed the available data with immunocombinations in mRCC, offering new perspectives in the treatment landscape of these patients. We discussed the main results of pivotal clinical trials of immune checkpoint inhibitors in the treatment of mRCC. Moreover, we discussed novel immuno-based treatments currently under investigation in ongoing clinical trials. Renal cell carcinoma is a particularly immunogenic tumor and immunotherapy is a pivotal treatment approach. A wide series of clinical trials is exploring novel promising immunocombinations in patients with renal cell carcinoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
